Literature DB >> 18066590

Renal oncocytoma with and without intravascular extension into the branches of renal vein have the same morphological, immunohistochemical, and genetic features.

Ondrej Hes1, Michal Michal, Radek Síma, Tomás Vanecek, Matteo Brunelli, Guido Martignoni, Naoto Kuroda, Isabel Alvarado Cabrero, Delia Perez-Montiel, Milan Hora, Tomás Urge, Miroslav Dvorák, Marie Jarosová, Ximing Yang.   

Abstract

We attempted to investigate the clinicopathological correlation of renal oncocytoma (RO) with renal vein extension. We identified seven ROs with extension into the branches of renal vein. The age of seven patients ranged from 61 to 82 years. Five cases were identified incidentally; two patients had gross hematuria. After surgery, all patients were alive and free of tumors with follow-up of 1 to 5 years (mean = 3.6). Oncocytomas measured from 2.2 to 7.5 cm. Renal vein extension was grossly suspected in five of seven cases and histologically confirmed in all seven cases. Tumor cells were positive for cytokeratins, mitochondrial-antigen (MIA), epithelial membrane antigen (EMA), and parvalbumin; five of seven tumors were focally positive for CD117. Ultrastructurally, the cytoplasm was packed by mitochondria. Molecular genetic analysis did not detect abnormal numbers of chromosomes 1, 2, 6, 7, 10, 17, and XY by fluorescence in situ hybridization, loss of heterozygosity on 3p and mutation of von Hippel-Lindau gene in all cases. Array comparative genomic hybridization analysis of two cases did not show any major genetic changes. Our conclusions are as follows: (1) renal oncocytomas may have intravascular extension to the branches of the renal vein; (2) renal oncocytomas with intravascular extension to the branches of the renal vein have the same morphological, immunohistochemical, and cytogenetic findings as have their counterparts without evidence of intravascular invasion; (3) the absence of metastases suggests an overall benign behavior of this tumor, but this has to be substantiated by further studies with a long-term follow-up; and (4) in a renal tumor with granular cytoplasm showing renal vein extension, it is necessary to carefully exclude renal cell carcinomas such as chromophobe RCC, oncocytic variant of papillary RCC, and granular variant of clear cell RCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18066590     DOI: 10.1007/s00428-007-0541-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  18 in total

1.  Renal oncocytoma: a clinicopathologic study of 70 cases.

Authors:  B Perez-Ordonez; G Hamed; S Campbell; R A Erlandson; P Russo; P B Gaudin; V E Reuter
Journal:  Am J Surg Pathol       Date:  1997-08       Impact factor: 6.394

2.  Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases.

Authors:  Marine Lefèvre; Jèrôme Couturier; Mathilde Sibony; Céline Bazille; Karine Boyer; Patrice Callard; Annick Vieillefond; Yves Allory
Journal:  Am J Surg Pathol       Date:  2005-12       Impact factor: 6.394

3.  Renal angiomyolipoma with extension into renal vein.

Authors:  S S Chen; A T Lin; K K Chen; L S Chang; K M Chang; H Chiang
Journal:  Br J Urol       Date:  1996-06

4.  Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).

Authors:  S Störkel; J N Eble; K Adlakha; M Amin; M L Blute; D G Bostwick; M Darson; B Delahunt; K Iczkowski
Journal:  Cancer       Date:  1997-09-01       Impact factor: 6.860

5.  Malignant angiomyolipoma of the kidney associated with hypercalcaemia.

Authors:  D J Byrne; P A Stewart; J W Lowe
Journal:  Br J Urol       Date:  1988-07

6.  Further evidence that renal oncocytoma has malignant potential.

Authors:  K E Psihramis; P Dal Cin; S P Dretler; G R Prout; A A Sandberg
Journal:  J Urol       Date:  1988-03       Impact factor: 7.450

7.  Oncocytoma-like angiomyolipoma. A clinicopathologic and immunohistochemical study of 2 cases.

Authors:  Guido Martignoni; Maurizio Pea; Franco Bonetti; Matteo Brunelli; John N Eble
Journal:  Arch Pathol Lab Med       Date:  2002-05       Impact factor: 5.534

Review 8.  The Heidelberg classification of renal cell tumours.

Authors:  G Kovacs; M Akhtar; B J Beckwith; P Bugert; C S Cooper; B Delahunt; J N Eble; S Fleming; B Ljungberg; L J Medeiros; H Moch; V E Reuter; E Ritz; G Roos; D Schmidt; J R Srigley; S Störkel; E van den Berg; B Zbar
Journal:  J Pathol       Date:  1997-10       Impact factor: 7.996

Review 9.  Angiomyolipoma of kidney.

Authors:  J N Eble
Journal:  Semin Diagn Pathol       Date:  1998-02       Impact factor: 3.464

10.  Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma.

Authors:  Matteo Brunelli; John N Eble; Shaobo Zhang; Guido Martignoni; Brett Delahunt; Liang Cheng
Journal:  Mod Pathol       Date:  2005-02       Impact factor: 7.842

View more
  4 in total

1.  LMP2, a novel immunohistochemical marker to distinguish renal oncocytoma from the eosinophilic variant of chromophobe renal cell carcinoma.

Authors:  Gang Zheng; Alcides Chaux; Rajni Sharma; George Netto; Patrizio Caturegli
Journal:  Exp Mol Pathol       Date:  2012-06-12       Impact factor: 3.362

2.  Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases.

Authors:  Petr Steiner; Milan Hora; Jan Stehlik; Petr Martinek; Tomas Vanecek; Fredrik Petersson; Michal Michal; Marie Korabecna; Ivan Travnicek; Ondrej Hes
Journal:  Virchows Arch       Date:  2013-01-08       Impact factor: 4.064

Review 3.  Imaging of Solid Renal Masses.

Authors:  Fernando U Kay; Ivan Pedrosa
Journal:  Radiol Clin North Am       Date:  2016-12-12       Impact factor: 2.303

Review 4.  Modern Pathologic Diagnosis of Renal Oncocytoma.

Authors:  Sara E Wobker; Sean R Williamson
Journal:  J Kidney Cancer VHL       Date:  2017-10-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.